Drug Profile
Research programme: cannabinoid-based therapeutics - Axim Biotechnologies
Alternative Names: Cannabidiol/Gabapentin; Cannbleph™Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Axim Biotech
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Antiemetics; Anxiolytics; Appetite stimulants; Behavioural disorder therapies; Cannabinoids; Eye disorder therapies; Muscle relaxants; Skin disorder therapies; Smoking cessation therapies
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Smoking withdrawal
- No development reported Atopic dermatitis; Attention-deficit hyperactivity disorder; Autistic disorder; Conjunctivitis; Infections; Post-traumatic stress disorders; Restless legs syndrome
Most Recent Events
- 28 May 2022 No recent reports of development identified for research development in Infections in USA
- 28 Aug 2021 No recent reports of development identified for preclinical development in Restless legs syndrome in Israel (PO, Gum)
- 28 Nov 2020 No recent reports of development identified for research development in Attention-deficit-hyperactivity-disorder in USA